Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction

Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteri...

Descripción completa

Detalles Bibliográficos
Autor principal: Hussain, Abid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251259/
https://www.ncbi.nlm.nih.gov/pubmed/34223148
http://dx.doi.org/10.1093/jacamr/dlab051
_version_ 1783717088672612352
author Hussain, Abid
author_facet Hussain, Abid
author_sort Hussain, Abid
collection PubMed
description Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi.
format Online
Article
Text
id pubmed-8251259
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82512592021-07-02 Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction Hussain, Abid JAC Antimicrob Resist Supplement Papers Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi. Oxford University Press 2021-06-15 /pmc/articles/PMC8251259/ /pubmed/34223148 http://dx.doi.org/10.1093/jacamr/dlab051 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Papers
Hussain, Abid
Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title_full Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title_fullStr Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title_full_unstemmed Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title_short Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
title_sort education: the role of the first siderophore cephalosporin fetcroja(®) (cefiderocol) in uk clinical practice: introduction
topic Supplement Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251259/
https://www.ncbi.nlm.nih.gov/pubmed/34223148
http://dx.doi.org/10.1093/jacamr/dlab051
work_keys_str_mv AT hussainabid educationtheroleofthefirstsiderophorecephalosporinfetcrojacefiderocolinukclinicalpracticeintroduction

Ejemplares similares